The Filing Desk

Arvinas

ARVN · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

ARVN · Last close · November 13, 2026
$6.82
Value Arvinas yourself

Arvinas' revenue fell 0.3% to $263 million in fiscal 2025. Its operating margin was −45.1%, up from −95.0% a year earlier. Free cash flow was −$276 million. It paid out $92 million in dividends and buybacks. The diluted share count fell 1.4%.

ARVINAS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001628280-26-011226 Updated
Revenue
$263M
0.3%
Operating margin
−45.1%
49.9 pts
Net income
−$81M
 
Free cash flow
−$276M
 
Return on equity
−16.2%
16.3 pts
Market cap
$446M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Arvinas does

Arvinas is a clinical-stage biotechnology company, meaning its medicines are still being tested in people. It develops a type of drug called a PROTAC, which is designed to use the body's own protein disposal system to remove proteins that cause disease, rather than just block them.

Its most advanced candidate is vepdegestrant, for a form of advanced breast cancer. The FDA had accepted its New Drug Application, the request to approve a drug for sale, as of the filing. Its other candidates target proteins linked to Parkinson's disease and a related brain disease, to certain cancers including pancreatic, colorectal and lung, to a type of lymphoma, and to a muscle condition.

Arvinas has never had revenue from product sales. It works with other companies on early research, including Pfizer and Genentech. In April and September 2025 it cut its workforce under a cost savings plan.

Its biggest risks, as it describes them

  • It has lost money since it started and may never be profitable.
  • It will need substantial more funding, and may have to cut programs if it cannot raise it.
  • Its PROTAC approach is unproven, so the time, cost and chance of success are hard to predict.
  • It has no approved products, and may not be able to commercialize its candidates.
  • Its 2025 workforce reductions may not save as much as expected and could disrupt its business.
From Arvinas's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Arvinas lost money in fiscal 2025: a net loss of $81 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,5031,2051,2611,039685
Debt incl. finance leases11111
Net debt (negative means net cash)−1,502−1,204−1,260−1,039−685
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage—————
Current ratio5.9x4.2x5.0x4.6x4.9x
Quick ratio5.9x4.2x5.0x4.6x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Arvinas' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Arvinas reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 83 of 85 of 8
Rule of 40−487.0%136.4%−105.3%
Altman Z''0.820.03−1.73
Accruals ratio−1.5%5.0%21.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailPassPass
Current ratio rosePassFailPass
Share count didn't riseFailFailPass
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score2 of 83 of 85 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Arvinas side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ArvinasFY25−0.3%−45.1%−105.0%——5
Iovance BiotherapeuticsFY2560.6%−153.1%−127.6%———Compare
Ligand PharmaceuticalsFY2560.4%15.3%18.2%4.9%−3.8x5Compare
VericelFY2516.4%4.0%9.0%———Compare
Adaptive BiotechnologiesFY2554.8%−20.6%−17.7%−37.2%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue81443265413178263263
Revenue growth—89.0%200.2%−39.8%107.0%145.2%−40.3%235.5%−0.3%
Gross profit—————————
Research and development294567108180315380348285
Operating income−25−44−52−121−188−263−402−250−118
Net income−24−42−70−119−191−282−367−199−81
Diluted EPS (US$)−15.08−25.45−2.13−3.02−3.82−5.31−6.62−2.77−1.14
Diluted shares (millions)2933405053567271
Cash flow
Cash from operations5−16−41−90559−274−348−259−274
Capital expenditure136657322
Free cash flow4−19−47−96555−280−351−261−276
Dividends paid000000000
Share buybacks0000000092
Acquisitions000000000
Stock-based compensation01220305776728844
Balance sheet at fiscal year end
Cash and short-term investments391882816891,5031,2051,2611,039685
Debt incl. finance leases022211111
Total assets671993027171,5821,2691,3051,091718
Total liabilities67637575800704645530284
Shareholders' equity−61137227642782565660562434
Margins and ratios
Gross margin—————————
Operating margin−326.7%−305.8%−119.8%−466.4%−351.5%−200.3%−511.5%−95.0%−45.1%
Net margin−317.3%−289.6%−163.5%−460.6%−356.3%−215.0%−467.9%−75.5%−30.8%
Free cash flow margin54.1%−132.3%−109.1%−371.0%1,034.9%−213.3%−446.8%−99.1%−105.0%
Rule of 40 (growth + FCF margin)—−43.3%91.1%−410.8%1,141.8%−68.2%−487.0%136.4%−105.3%
Return on capital—————————
Return on equity—−110.1%−38.7%−27.5%−26.8%−42.0%−60.0%−32.6%−16.2%
Return on assets—−31.2%−28.1%−23.4%−16.6%−19.8%−28.6%−16.6%−8.9%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Arvinas' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Arvinas.